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Although most HTLV-1-infected individuals remain
asymptomatic carriers (AC) during their lifetime, 2-5%
will develop either Adult T-cell Leukemia (ATL) or the
neurological disorder HTLV-1-associated myelopathy/
tropical spastic paraparesis (HAM/TSP). To better
understand differential gene expression in HTLV-1-asso-
ciated disease, we examined the mRNA profiles of CD4+
T-cells isolated from ATL, HAM/TSP, AC and non-
infected controls. Using genomic approaches, we identi-
fied gene signatures that discriminate between HTLV-1
clinical outcomes. Major activated cellular pathways
included antimicrobial defense (KLRB1/SPN/SELPLG),
innate immune sensing (TRAF3/AIM2/TLR2/TLR4/
IKBKG/STAT3), cell adhesion and chemotaxis (CXCR4/
CD2/CD63/CD48/CCL14/SPN/CCL13), thus supporting
the idea of global immune disruption during HTLV-1
infection. Among the many genes identified, the sup-
pressor of cytokine signaling 1, SOCS1, was upregulated
in HAM/TSP and AC. SOCS1 expression positively cor-
related with high HTLV-1 mRNA load that is character-
istic of HAM/TSP patients. SOCS1 inhibited cellular
antiviral signaling during HTLV-1 infection by degrad-
ing IRF3, an essential transcription factor in the inter-
feron pathway. This novel mechanism of viral evasion of
the innate immune response can be directly related to
the efficiency of HTLV-1 replication in patients with
HAM/TSP. Despite SOCS1 ability to limit antiviral
responses, CD4+ T-cellsf r o mH A M / T S Pp a t i e n t s
revealed a striking upregulation of IFN stimulated gene
expression, viral host restriction factors and pro-inflam-
matory genes. We hypothesize that the magnitude of
innate immune responses against HTLV-1 during de
novo infection may predict clinical outcome; patients
mounting a sustained/low antiviral response to HTLV-1
may remain AC with a low probability to progress to
ATL, while those displaying an aberrant/high IFN
response may progress to HAM/TSP.
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